Novel ADC Solidifies Role in Breast Cancer
- PMID: 31843763
- DOI: 10.1158/2159-8290.CD-NB2019-139
Novel ADC Solidifies Role in Breast Cancer
Abstract
The antibody-drug conjugate trastuzumab deruxtecan might become a promising new treatment option for patients with metastatic HER2-positive breast cancer whose disease has progressed after multiple therapies. In a phase II trial, the drug was associated with a high objective response rate and long median progression-free survival, although some patients developed serious side effects.
©2020 American Association for Cancer Research.
Comment on
-
Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer.N Engl J Med. 2020 Feb 13;382(7):610-621. doi: 10.1056/NEJMoa1914510. Epub 2019 Dec 11. N Engl J Med. 2020. PMID: 31825192 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous